Artificial intelligence is showing promise in improving the detection and management of idiopathic pulmonary fibrosis (IPF), ...

In its second-quarter earnings release, the company said that in July and August 2025 it analyzed interim data from the ...

A new study offers encouraging news for older adults with chronic respiratory conditions who may struggle to access traditional gym-based rehabilitation programs. Researchers found that pulmonary ...

Analysts have recently evaluated Liquidia and provided 12-month price targets. The average target is $28.83, accompanied by a ...

Learn more about whether Amneal Pharmaceuticals, Inc. or Liquidia Corporation is a better investment based on AAII's A+ ...

We recently published 10 Stocks on Euphoria. Are You Holding Any? Liquidia Corp. (NASDAQ:LQDA) is one of the best-performing ...

A 28-year-old woman was admitted to the hospital because of severe hypoxemia and right heart failure that had been caused by rapidly progressive pulmonary hypertension. A diagnosis was made.

Shiv Sena(UBT) supported the Supreme Court's orders upholding the Bombay High Court's stay on feeding pigeons and asking the ...

Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in ...

EMERYVILLE, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its 2025 second quarter and year to date financial results and ...

In an increasingly challenging environment for scientific research funding, the American Lung Association Research Institute today announced the opening of its 2026-2027 Research Awards and Grants ...

The FDA has approved Insmed’s brensocatib, the first treatment for non-cystic fibrosis bronchiectasis, a chronic and progressive lung disease affecting about 500,000 people in the U.S. The drug was ...